<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101204</url>
  </required_header>
  <id_info>
    <org_study_id>MSF</org_study_id>
    <nct_id>NCT01101204</nct_id>
  </id_info>
  <brief_title>The Effects of Hypolipemic and Antidiabetic Treatment on Cytokines</brief_title>
  <acronym>MSF</acronym>
  <official_title>Effects of High and Low Doses of Metformin, Fenofibrate and Simvastatin, Administered Together and in Sequence With Lifestyle Intervention on Lipid Profile, Glucose Metabolism, Low-grade Inflammation and Hemostasis in Patient's Blood Plasma in Type 2 Diabetic Patients With Serious Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is planned to show whether combined hypolipemic and antidiabetic therapy with
      various daily dosages influence the fasting plasma glucose, insulin sensitivity and
      proinflammatory cytokines in diabetic and dyslipidemic subjects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antiinflammatory effects of combined antidiabetic and hypolipemic treatment</measure>
    <time_frame>30 days</time_frame>
    <description>As inflammatory effects we measure the difference in serum concentration before and after the treatment of the following proinflammatory cytokines:
Interleukin 1
TNF alpha
Interleukin 6
Interleukin 10
hsCRP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>30 days</time_frame>
    <description>Assesed by HOMA (Homeostatic Model of Assessment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters</measure>
    <time_frame>30 days</time_frame>
    <description>Assessed using:
Fibrinogen
PAI-1</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes</condition>
  <condition>Dyslipidemia</condition>
  <condition>Inflammation</condition>
  <condition>Cytokines</condition>
  <arm_group>
    <arm_group_label>M1000 S10 F100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin 1000mg, fenofibrate 100mg and simvastatin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M1000 S10 F267</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin 1000mg, fenofibrate 267mg and simvastatin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M1000 S40 F100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin 1000mg, fenofibrate 100mg and simvastatin 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M1000 S40 F267</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin 1000mg, fenofibrate 267mg and simvastatin 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M2500 S10 F100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin 2500mg, fenofibrate 100mg and simvastatin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M2500 S10 F267</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin 2500mg, fenofibrate 267mg and simvastatin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M2500 S40 F267</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin 2500mg, fenofibrate 267mg and simvastatin 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M2500 S40 F100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin 2500mg, fenofibrate 100mg and simvastatin 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic Lifestyle Change</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Only therapeutic lifestyle change</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg</intervention_name>
    <description>Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.</description>
    <arm_group_label>M1000 S10 F100</arm_group_label>
    <arm_group_label>M1000 S10 F267</arm_group_label>
    <arm_group_label>M1000 S40 F100</arm_group_label>
    <arm_group_label>M1000 S40 F267</arm_group_label>
    <arm_group_label>M2500 S10 F100</arm_group_label>
    <arm_group_label>M2500 S10 F267</arm_group_label>
    <arm_group_label>M2500 S40 F267</arm_group_label>
    <arm_group_label>M2500 S40 F100</arm_group_label>
    <arm_group_label>Therapeutic Lifestyle Change</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age (35-64yr)

          -  Primary hyperlipidemia (Total cholesterol &gt;200mg/dl, Triglycerides &gt;150mg/dl)

          -  Type 2 Diabetes

          -  For women:

          -  Menopause (&gt;12 months)

          -  Post hysterectomy

          -  Mechanical contraception

          -  Obtained informed consent

        Exclusion Criteria:

          -  Secondary hyperlipidemia

          -  Morbid obesity (BMI&gt;40kg/m2)

          -  Alcohol or drug abuse

          -  Acute or chronic inflammation

          -  Congestive Heart Failure (NYHA III or IV)

          -  Unstable Ischaemic Heart Disease

          -  Moderate or severe hypertension

          -  Cancer in less than 5 years

          -  Chronic kidney disease (stage III-V)

          -  Liver failure

          -  Oral contraception

          -  Not compliant patient

          -  Laboratory results:

          -  alanine transferase (&gt;3xULN)

          -  creatine kinase (&gt;5xULN)

          -  haemoglobin (&lt;10/dl)

          -  PLT (&lt;100G/l)

          -  WBC (&lt;3,5G/l or &gt;10G/l)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Krzysztof Labuzek, MD, PhD</last_name>
    <phone>+48 32 252 39 02</phone>
    <email>lbuldak@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology</name>
      <address>
        <city>Katowice</city>
        <zip>40752</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krzysztof Labuzek, MD, PhD</last_name>
      <phone>+48 32 252 39 02</phone>
      <email>lbuldak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Łukasz Bułdak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bogusław Okopień, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krzysztof Labuzek, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>July 5, 2012</last_update_submitted>
  <last_update_submitted_qc>July 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Silesia</investigator_affiliation>
    <investigator_full_name>Bogusław Okopień</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

